Platinum resistant recurrent ovarian cancer

Author: qqjy

August undefined, 2024

Webb8 apr. 2024 · Platinum-resistant disease: For a recurrence that develops less than 6 months after the completion of initial therapy, one of the following single-agent regimens may be considered: Pegylated... WebbOvarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Platinum-Resistant Ovarian Cancer - an overview - ScienceDirect

Webbdefinition of platinum resistance In this substudy, platinum resistance was classified further according to response to previous anticancer treatments. PPR was defined as progression <6 months after completing first-line platinum-based chemotherapy (one or two chemotherapy regimens allowed). WebbIn platinum resistant ovarian cancer, nivolumab demonstrated in a phase II trial encouraging safety and clinical efficacy with a RR of 15% (Hamanishi et al., 2015). From: Critical Reviews in Oncology/Hematology, 2016 Related terms: Neoplasm Combination Therapy Therapeutic Procedure Patient Inpatient Paclitaxel Progression Free Survival gaz detektor

Treatment of platinum-resistant ovarian cancer - PubMed

Webb11 apr. 2024 · Niraparib was authorized as a maintenance treatment for platinum-sensitive recurrent ovarian cancer in December 2024 and as first-line maintenance therapy in October 2024 in China . At the beginning of the study period, due to economic reasons, niraparib was often reserved as a last resort when patients were resistant or intolerable … Webb9 sep. 2024 · The congress will take place from September 16 – 21, 2024. “We are extremely excited by the potential of relacorilant to treat women with recurrent platinum-resistant ovarian cancer,”... Webb21 aug. 2024 · Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was hypothesized that prolonging PFI with single-agent non-PBC (NPBC) may offer a strategy to improve overall outcome. austria vienna ii vs amstetten h2h

Platinum-resistant recurrent ovarian cancer with long survival on ...

Fallopian Tube Cancer Treatment Protocols - Medscape

WebbAfter recurrence, response rates to second-line chemotherapy for platinum-sensitive patients are 30% or higher; however, patients with platinum-resistant disease have significantly lower response rates of 10%-25% to chemotherapeutic agents, such as liposomal doxorubicin, topotecan, taxanes, etoposide, and gemcitabine [ 2 ]. WebbResistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the … gaz dragon ballWebbAbstract 807O Background Nivolumab, a human anti-programmed death-1 (PD-1) receptor monoclonal antibody, is effective against some cancers. A phase II trial has supported the efficacy of nivolumab in platinum-resistant ovarian cancer, but a randomized trial is required to confirm its efficacy. gaz dilué

"WebbDiscussion. The AVF 2949g trial was a clinical study on platinum-resistant recurrent ovarian cancer. Because GI perforation was observed in five (23.8%) of the 21 patients … " - Platinum resistant recurrent ovarian cancer

Platinum resistant recurrent ovarian cancer

Role of Immunotherapy in Platinum-Resistant Ovarian Cancer OTT

WebbOvarian cancer is the leading cause of death for patients with gynecologic malignancies, and the standard first-line treatment is platinum-based chemotherapy and tumor cytoreductive surgery. 1 Although most ovarian cancer patients are sensitive to platinum-based chemotherapy, about 80% patients relapse within 1 to 2 years after initial … Webbför 2 dagar sedan · As part of the phase 3 GLORIOSA study (NCT05445778), a clinical trial is evaluating the safety and efficacy of the antibody drug conjugate (ADC) mirvetuximab soravtansine (Elahere) as maintenance therapy for patients with folate receptor-alpha (FRα)-positive recurrent platinum-sensitive ovarian cancer. 1 In the multicenter, open …

Did you know?

Webb23 jan. 2024 · Background: The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We … WebbPujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.. (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian …

WebbPurpose: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. Patients and methods: We … WebbThis study aimed to further explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC). Methods: Totally, 105 patients with recurrent PROC receiving apatinib plus chemotherapy (N = 51) and chemotherapy alone (N = 54) were retrospectively enrolled in this cohort study.

Webb2 feb. 2024 · There are a number of approaches to develop effective and tolerable medicines in platinum-resistant recurrent ovarian cancer—at least 4 come to mind. Tumor treating fields are active in chemotherapy-resistant tumors such as glioblastoma multiforme in thoracic mesothelioma. Webb9 mars 2024 · For patients with platinum-sensitive recurrent ovarian cancer, we usually choose carboplatin (carbo) in combination with paclitaxel (PAC) as the first-line standard chemotherapy regimen, but this regimen exhibits more non-hematologic toxicity, which results in early discontinuation of treatment.

Webb6 maj 2024 · At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance. The combination of anti-angiogenic drugs and PARPi can play a synergistic anti-tumor role and achieve good efficacy in platinum-sensitive recurrent ovarian cancer.

WebbBackground: The purpose of this study was to observe the role of secondary cytoreductive surgery in platinum-resistant recurrent ovarian cancer (OC) patients. Methods: We … gaz dépannage 28Webb12 aug. 2024 · Phase 3 OVAL Trial With VB-111 in Platinum-Resistant Ovarian Cancer to Continue Aug 12, 2024 Kristi Rosa The independent data safety monitoring committee has unanimously recommended that the... gaz détonationWebb23 jan. 2024 · Effective and well tolerated treatment for platinum-resistant ovarian cancer remains a substantial unmet need. Despite the introduction of targeted and immunological therapies for its management, platinum-based chemotherapy with carboplatin or … gaz du sang vidéoWebb1 maj 2014 · Purpose: In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is … gaz dyneffWebbPlatinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long … gaz duWebbThe mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment modalities have tested in this setting with discouraging … gaz détendeurWebbPrognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies … austria vienna jogos